Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

Some Brilacidin single dose DD. It probably will

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72447
Posted On: 04/12/2016 9:21:47 PM
Posted By: F1ash
Some Brilacidin single dose DD. It probably will be first choice in renal impaired individuals amoung others. Delayed hypersensitivity could prevent early release from the hospital if using the other drugs thus negating some cost savings due to the competition's long half life.


"Published Online: Wednesday, March 23, 2016
Orbactiv and Dalbavancin: One and Done

Oritavancin (Orbactiv) and dalbavancin (Dalvance) are semisynthetic lipoglycopeptide antibiotics with activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus. They both received FDA approval in 2014 for the treatment of acute bacterial skin and skin structure infections (ABSSSI).



The game-changing property of these antibiotics is their one-time dosing, although dalbavancin can be given as a 2-dose regimen. They also have long terminal half-lives of 245 hours and 346 hours for oritavancin and dalbavancin, respectively.

Both antibiotics are bactericidal and inhibit the transglycosylation and transpeptidation step of cell wall biosynthesis. Oritavancin also disrupts of bacterial membrane integrity, but dalbavancin does not. Given oritavancin’s dual mechanisms, the drug may have increased efficacy and reduced risk of resistance.

From an emergency department standpoint, the possibility of avoiding admission among stable patients with ABSSSI is appealing.

Both drugs are costly, with wholesale prices around $3000 to $5000, but consider the cost of vancomycin. My guess is that it’s probably not that much higher, but other pertinent pros and cons for oritavancin and dalbavancin should be taken into account when deciding whether to use these antibiotics in the emergency department.

Pros
Assures compliance because only 1 dose is needed.
Targets common organisms in ABSSSI.
Convenient for patients to avoid admission and pharmacy visits.
No drug-level monitoring is required.
Peripherally inserted central catheter isn’t needed for outpatient antibiotic therapy.
Safety and efficacy are comparable with vancomycin’s in clinical trials for ABSSSI.
Cons
They’re expensive.
Delayed hypersensitivity reactions given long duration.
If treatment fails, there’s the question about which antibiotic to use next.
Oritavancin is a 3-hour infusion and dalbavancin is a 30-minute infusion.
Both antibiotics are only compatible with 5% dextrose in water.
Little data on oritavancin dosing in severe renal insufficiency.
Use of intravenous (IV) heparin is contraindicated with oritavancin for 120 hours because of false elevations of the activated partial prothrombin time.
While I believe that the use of oritavancin and dalbavancin should be rare, there may be certain cases and circumstances where the antibiotics could be ideal. Although I’m not generally a proponent of giving IV antibiotics to patients who will be discharged home, avoiding admission for patients who may need them is an attractive option.


http://www.pharmacytimes.com/contributor/matt...e-and-done


(1)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us